What measures can be taken to prevent Clostridioides difficile (C. diff) recurrence in a patient with a history of C. diff who is taking antibiotics?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025 • View editorial policy

From the Guidelines

To prevent C. difficile infection recurrence in a patient with a history of C. diff who requires antibiotics, consider prophylactic oral vancomycin (125 mg once daily) or fidaxomicin (200 mg once daily) during and for 5-7 days after completion of the antibiotic course, as recommended by the 2021 focused update guidelines by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) 1. When possible, choose narrow-spectrum antibiotics, minimize treatment duration, and avoid high-risk antibiotics like fluoroquinolones, clindamycin, and broad-spectrum cephalosporins.

Key Considerations

  • Probiotics containing Saccharomyces boulardii or Lactobacillus species may provide additional protection when started with antibiotics.
  • Ensure strict infection control measures including handwashing with soap and water (alcohol-based sanitizers are less effective against C. diff spores).
  • For patients with multiple recurrences, consider fecal microbiota transplantation as a preventive measure before starting antibiotics, as suggested by the AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases 2. These approaches work by either directly inhibiting C. difficile growth (vancomycin/fidaxomicin), minimizing disruption to the protective gut microbiome, or restoring beneficial bacteria that compete with C. difficile for resources and prevent its proliferation.

Additional Recommendations

  • Bezlotoxumab, a human monoclonal antibody, may be considered for patients with a high risk of recurrence, particularly those with severe CDI or immunocompromised patients 3.
  • Fecal microbiota transplantation should be performed with appropriately screened donor stool, and special testing may be necessary, especially in immunocompromised patients 2.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Measures to Prevent C. diff Recurrence

To prevent Clostridioides difficile (C. diff) recurrence in a patient with a history of C. diff who is taking antibiotics, several measures can be taken:

  • Fecal Microbiota Transplantation (FMT): FMT has been shown to be effective in preventing C. diff recurrence, with studies demonstrating higher success rates than vancomycin, fidaxomicin, or placebo 4, 5.
  • Standardized Microbiome Restoration Therapies: These therapies, such as SER-109 and RBX2660, have been approved by the US Food and Drug Administration for recurrent C. diff infection and have demonstrated significant reductions in recurrence rates 4.
  • Antibiotic Neutralization Strategies: Agents that neutralize antibiotics in the gut, such as bezlotoxumab, can help prevent C. diff recurrence 6, 7.
  • Probiotics: While the evidence is limited, certain probiotic strains, such as Lactobacillus rhamnosus GG and Saccharomyces boulardii, have been studied for their potential to prevent C. diff infection 8.
  • Alternative Treatment Approaches: Other therapeutic strategies, such as immunomodulation and drug repurposing, are being explored to treat C. diff infection 6, 4.

Key Considerations

When considering these measures, it is essential to note that:

  • FMT has been shown to be superior to fidaxomicin and vancomycin for treatment of recurrent C. diff infection 5.
  • Standardized microbiome-based therapies provide a promising alternative to FMT, with significant reductions in recurrence rates 4.
  • Antibiotic stewardship is crucial in preventing C. diff recurrence, and alternative treatment approaches should be considered when possible 6, 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2023

Research

Update of treatment algorithms for Clostridium difficile infection.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018

Research

Probiotics for Prevention and Treatment of Clostridium difficile Infection.

Advances in experimental medicine and biology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.